article thumbnail

ICON partners with US Government for clinical trials of Covid-19 vaccines

Pharmaceutical Technology

ICON will conduct Phase IIb clinical trials for the US BARDA-selected Covid-19 vaccine candidates as part of ‘Project NextGen’.

article thumbnail

Successful clinical trial for re-engineered Covid vaccine 

Drug Discovery World

The University of Queensland’s re-engineered clamp platform has produced a vaccine that is equally safe and virus-neutralising as an approved Covid vaccine considered among the best in its class. The Clamp2 trial group showed a 2.5-fold fold boost in neutralising ‘titres’ and it was 2.1 in the Novavax group.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

HIV vaccine being developed by Johnson & Johnson fails clinical trial

STAT News

Yet another experimental HIV vaccine has failed. The National Institute of Allergy and Infectious Diseases reported Wednesday that a Phase 3 clinical trial of a vaccine was stopped because the vaccine was ineffective at preventing HIV infection. Read the rest…

article thumbnail

“Game-changing” personalised cancer vaccine enters UK clinical trials   

Drug Discovery World

A clinical trial of a personalised mRNA cancer vaccine for melanoma patients has been launched in the UK. The vaccines are personalised to each patient after a tumour sample is removed during surgery and then analysed using DNA sequencing. in the combination arm and 62.2%

article thumbnail

Pfizer, after delay, completes enrollment in Lyme vaccine trial

Bio Pharma Dive

The announcement ends a lengthy setback that began when the company and partner Valneva accused a clinical trial site operator of study misconduct.

Trials 273
article thumbnail

Naobios manufactures FluGen Inc’s M2SR influenza vaccine candidate for upcoming clinical trials

Pharma Mirror

Nantes, France, Naobios, a CDMO (Contract Development and Manufacturing Organization) providing bioprocess development and GMP production of clinical batches of viral vaccines BSL2/BSL3, oncolytic viruses and viral vectors, today announces the next phase in its partnership with FluGen, Inc., The company’s.

article thumbnail

Pharma Mirror Q&A with Jane Myles, Vice President of Clinical Trial Innovation at Curebase

Pharma Mirror

This webinar focused on the need for a coordinated clinical trials enterprise, one that can quickly characterize emerging viral threats and evaluate the effectiveness of vaccines, therapeutics, and other countermeasures across a diversity of trial participants.